Skip to main content

Table 3 Analytical results for nitrosamines presented as average ± standard deviation for triplicate measurements

From: Harmful and potentially harmful constituents (HPHCs) in two novel nicotine pouch products in comparison with regular smokeless tobacco products and pharmaceutical nicotine replacement therapy products (NRTs)

Analyte

Units

Limit of quanification

ZYN (dry)

ZYN (moist)

NRT (lozenge)

NRT (gum)

Snus (pouch)

Moist snuff (loose)

Moist snuff (pouch)

NAB (N-Nitrosoanabasine)

µg/g

0.01

*

*

*

*

0.02 ± 0

0.30 ± 0.02

0.24 ± 0.01

NAT (N-Nitrosoanabatine)

µg/g

0.01

*

*

*

*

0.31 ± 0.02

3.50 ± 0.10

2.43 ± 0.06

NDELA (N-Nitrosodiethanolamine)

ng/g

25

*

*

*

*

*

*

*

NDMA (N-Nitrosodimethylamine)

ng/g

0.20

*

*

*

*

0.24 ± 0.01

7.90 ± 0

2.67 ± 0.06

NMOR (N-Nitrosomorpholine)

ng/g

10

*

*

*

*

*

*

*

NNK (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone)

µg/g

0.01

*

*

*

*

0.19 ± 0.01

2.27 ± 0.05

0.92 ± 0.01

NNN (N-Nitrosonornicotine)

µg/g

0.01

*

*

*

*

0.44 ± 0.01

3.63 ± 0.06

2.53 ± 0.06

NPIP (N-Nitrosopiperidine)

ng/g

10

*

*

*

*

*

*

*

NPYR (N-Nitrosopyrrolidine)

ng/g

10

*

*

*

*

*

54 ± 3

*

NSAR (N-Nitrososarcosine)

ng/g

25

*

*

*

*

*

150 ± 17

177 ± 59

  1. * The measured analyte was below the quantification limit